This review article (1995) looks back at the pre-renaissance studies on psychedelics.
Clinical research with hallucinogens has resumed after a generation's hiatus. To place these new studies in context, this article reviews the history of hallucinogens' use and abuse, discusses their pharmacological properties, and highlights previous human studies. Research with Iysergic acid diethylamide and related hallucinogens with thousands of patients and control subjects was associated with acceptable safety when subjects were carefully screened, supervised, and followed up. Data were generated regarding hallucinogens' psychopharmacology, overlap with endogenous psychoses, and psychotherapeutic efficacy. Current American and European studies emphasize systematic psychopharmacology, in addition to psychotherapy protocols. Human hallucinogen research will help define unique mind-brain interfaces, and provide mechanistic hypotheses and treatment options for psychiatric disorders. It is critical that human hallucinogen research in the l990s make use of state of the art methodologies, or consensually define when modifications are required. Training and supervisory issues also must be explicitly addressed.
The review situates contemporary human research with hallucinogens against a long history of cultural, recreational, and clinical use. Earlier work with lysergamides (notably LSD), phenethylamines (mescaline), and indolealkylamines (psilocybin, DMT) generated substantial clinical and psychopharmacological data in the mid-20th century but was interrupted for about a generation. The author emphasises three motivations for renewed research: (1) hallucinogens produce complex syndromes that probe many aspects of human cognition, affect, perception, and volition and so offer a window on mind–brain relationships; (2) drug-induced states overlap in some respects with endogenous psychoses, suggesting potential mechanistic and therapeutic insights; and (3) reports of psychotherapeutic enhancement, and continued recreational use and abuse, argue for better-characterised, safe clinical research and treatments for adverse sequelae. This article therefore aims to review the history, pharmacology, human experimental data, therapeutic applications, adverse effects, and regulatory context of classical and related hallucinogens, and to outline methodological, training, and future-research priorities for restarting human hallucinogen research. The author frames the review as both a synthesis of existing human data and a set of pragmatic recommendations for designing rigorous, state-of-the-art studies in the 1990s and beyond.
Papers cited by this study that are also in Blossom
Cohen, S. · Journal of Nervous and Mental Disease (1980)
Gillin, J. C., Kaplan, J., Stillman, R. et al. · American Journal of Psychiatry (1976)
Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)
Rinkel, M., Atwell, C. R., DiMascio, A. et al. · New England Journal of Medicine (1960)
Strassman, R. J. · Journal of Nervous and Mental Disease (1984)
This is a narrative, integrative review drawing on historical reports, preclinical pharmacology, human psychopharmacology studies, clinical series, epidemiological data, and surveys of earlier clinical research. The extracted text does not provide a formal methods section describing search strategy, inclusion criteria, databases searched, or a systematic appraisal process; hence the review appears to be selective and discursive rather than a systematic review or meta-analysis with prespecified methods. The author summarises evidence from a variety of sources, including large historical clinical datasets (notably thousands of patients and volunteers exposed to LSD and mescaline in mid-century research), national survey data (NIDA statistics on adolescent LSD use), animal models (drug discrimination paradigms), human pharmacological challenge and blockade studies, psychometric instrument development (including the Hallucinogen Rating Scale, HRS), and contemporary Phase I and psychopharmacology protocols being undertaken at several US and European centres. Where available, quantitative counts and rates from prior surveys are reported; however, details of how studies were selected for inclusion in the review are not specified in the extracted text.
Historical clinical research: Large mid-20th-century clinical programmes administered LSD and related compounds to thousands of subjects (total exposures cited as over 25,000 doses in more than 5,000 subjects) and, when subjects were carefully screened, supervised, and followed, reported generally acceptable safety profiles. Early uncontrolled psychotherapeutic series suggested short-term clinical improvements in depression, substance abuse, autism, and palliative care, but methodological weaknesses (small samples, lack of controls and blinded raters, variable outcomes) limited definitive conclusions. Epidemiology and legal status: NIDA survey data cited an increase in 12-month LSD use among high school seniors from 4.8% to 5.6% between 1988 and 1992, contrasting with declines in some other drugs; lifetime hallucinogen prevalence approximated that for cocaine and exceeded heroin by several-fold. Hallucinogens are placed in Schedule I under US law, with attendant legal and regulatory constraints; religious exemptions (e.g. peyote in the Native American Church) and legislative developments are noted. Pharmacology and mechanisms: The review emphasises serotoninergic mechanisms, especially 5-HT1A and 5-HT2A/C receptor involvement, as central to classical hallucinogens' effects, while acknowledging roles for noradrenergic, dopaminergic and cholinergic systems. Tolerance and cross-tolerance develop rapidly for classical agents; DMT is an exception, showing little behavioural tolerance and producing full effects in LSD-tolerant subjects. Animal drug-discrimination models identify some limitations because non-hallucinogens can be LSD-like in animals, and psilocybin did not substitute reliably in certain paradigms, underscoring the need for human studies. Human measurement: Earlier rating instruments for LSD existed but had limitations. The author reports development of the Hallucinogen Rating Scale (HRS), drafted from interviews with experienced users and pilot DMT studies; the HRS groups items into six clinical clusters (somaesthesia, affect, perception, cognition, volition, and intensity) and is reported to be sensitive to dose-related subjective effects, sometimes more so than biological measures. Drug characteristics and administration: The review categorises hallucinogens by temporal profile (ultra-short to ultra-long acting), noting that pharmacokinetics and access to brain sites largely explain onset and duration. Routes of administration (intravenous, intramuscular, oral, intraspinal) influence time course, and there is debate about downstream mechanisms but evidence for very rapid onset under some routes. Hallucinogens and psychosis: Findings on similarity to schizophrenia are mixed. Acute positive-symptom patients show more overlap with psychedelic phenomena than chronic negative-symptom patients, who often show blunted responses. The DMT/short-chain tryptamines have been considered putative endogenous ‘schizotoxins’ because of biochemical plausibility and some correlative data, but peripheral measures have not consistently differed between patients and controls. Psychotherapy studies: Two broad therapeutic models are described. The psycholytic approach used repeated low-to-moderate doses adjunctive to ongoing psychotherapy, while the psychedelic model used one or a few high-dose sessions to elicit peak or mystical-type experiences. Earlier uncontrolled reports suggested benefit in substance abuse, palliative care, and other conditions, but controlled studies and longer follow-up often attenuated those positive impressions; a review of 31 alcoholism studies was inconclusive given methodological heterogeneity. Adverse effects: Adverse outcomes are categorised as acute (brief panic reactions, psychotic reactions requiring hospitalisation), subacute (flashbacks; reported incidence ranges widely, with 15%–77% in some series, though DMT studies reported 5%–10% in experienced volunteers), and chronic (functional syndromes resembling enduring negative-symptom disorders, persistent perceptual disorders). A survey of clinical research reported very low rates of attempted or completed suicide in normal volunteers (0/1,000) and low but non-zero rates in patient populations (attempted 1.2/1,000, completed 0.4/1,000), with psychotic reactions over 48 hours of 0.8/1,000 in volunteers and 1.8/1,000 in patients. Data on mutagenicity and teratogenicity were inconsistent and not replicated; the author advises excluding pregnant women or those not using reliable contraception. Contemporary and ongoing research: At the time of writing, Phase I and psychopharmacology studies with DMT, ibogaine, MDMA, ketamine, psilocybin and mescaline were underway at multiple US and European centres; some European clinical psychodynamic work had been ongoing without published outcome data. Identified future research priorities include exploiting different temporal profiles of drugs for specific experimental goals, refining measurement (subjective measures such as HRS shown to be sensitive), exploring non-serotonergic mechanisms (notably dopamine), combining pharmacological blockade studies, structure–activity work, and advanced brain imaging and electrophysiology.
The author interprets the body of evidence as supportive of cautious renewal of human hallucinogen research, arguing that these compounds can illuminate mind–brain interfaces, generate mechanistic hypotheses relevant to psychoses, and potentially augment psychotherapeutic interventions. While acknowledging promising signals from earlier clinical work, the review stresses that many of those studies lacked adequate controls, independent raters, standardised outcomes, and sufficient follow-up; placebo and dosing issues complicate interpretation of past psychotherapeutic findings. Practical concerns and recommendations receive considerable emphasis. The author urges rigorous subject selection, preparation, supervision, and follow-up; use of experienced hallucinogen users in early psychopharmacology research to improve informed consent and reduce traumatic reactions; use of the lowest effective doses for clinical populations; and stepwise dosing if high-dose sessions are necessary. Training and supervisory arrangements for investigators are recommended, with a call for specialised training or certification to reduce risks arising from transference/countertransference, suggestibility, and potential ethical boundary violations. The review also highlights the importance of set and setting—participants' expectations, personality, and the physical and interpersonal environment—and recommends that these variables be explicitly considered in study design. For future research, the author proposes methodological innovations: standardised subjective instruments (HRS), within-subject designs for sensitivity, pharmacological blockade and pretreatment studies to understand mechanism and to develop interventions for acute adverse reactions, comparative within-subject evaluations of congeners to define structure–activity relationships, and application of modern neuroimaging and electrophysiological techniques. Clinical avenues proposed include hybrid psychotherapeutic models that combine psycholytic and psychedelic elements, studies in palliative care and PTSD, and carefully controlled substance-abuse interventions. The author also notes legal and regulatory hurdles and calls for careful engagement with oversight agencies. Limitations acknowledged include the selective and often anecdotal nature of much historical data and the absence of standardised methods in many earlier trials, which constrain the strength of conclusions and necessitate contemporary, methodologically rigorous studies.
Renewal of human hallucinogen research is encouraging but must be pursued cautiously. The author concludes that contemporary studies should employ state-of-the-art methodologies, meticulous selection, screening, preparation, supervision, and follow-up of subjects, and explicit attention to the training and characteristics of investigators and the research setting. Given the controversial history and potential for serious psychiatric sequelae, these procedural safeguards and regulatory oversight are essential for safe and scientifically valid progress in the field.
Many terms have been used to describe the effects of these drugs, including psychedelic (mind manifesting), psychodysleptic (disturbing the mind), phantasticant, psychotogen, oneirogen (producing dreams), entheogen (generating religious experience), phanerothyme (making feelings visible), psychotomimetic, and schizotoxin. Psychedelic represents the nonmedical, recreational, and illicit use of these drugs, while hallucinogen refers to these compounds within a medical-legal context. The "classical" hallucinogens belong to several chemical families: phenethylamines (e.g., mesc aline), indolealklyamines (e.g., psilocybin and N,N-dimethyltryptamine [DMT]), and lysergamides (e.g., LSD and morning glory seeds). 3,4-Methylene-dioxymethamphetamine (MDMA) ("X," "XTC") is a methoxylated amphetamine (phenethylamine), and produces effects that overlap those of classical compounds. Low doses of the dissociative anesthetics, phencyclidine and ketamine, and antimuscarinic agents) also share subjective properties with the hallucinogens. However, hallucinogens do not produce anesthesia at high doses, as do the former compounds, nor is there a clouding of consciousness at "psychedelic" doses, as with the latter. A clinically useful manner of representing hallucinogens refers to their temporal properties: onset, peak effect, and duration of action. An "ultra-short-acting" drug's onset is less than 1 minute, peak effects occur within 5 minutes, and duration is 30 minutes or less. Intravenous DMT is an example. A "short-acting" hallucinogen's onset is between 5 and 15 minutes, peak effects are within 15 to 60 minutes, and duration is 1 to 2 hours (e.g., intramuscular N,N-diethyltryptamine;. "Intermediate-acting" hallucinogens include the orally active tryptamine psilocybin. Onset is within 15 to 30 minutes, peak effects are at 1 to 3 hours, with duration up to 6 hours. "Long-acting" hallucinogens include oral LSD and mescaline, with onset at 30 to 90 minutes, peak effects at 3 to 5 hours, and duration of 8 to 12 hours. "Ultra-long-acting" compounds include the poorly characterized African plant drug ibogaine. Duration of action may last 18 to 24 hours.
Hallucinogen use in the United States remained relatively constant from the late 1960s to the Written by Rick J.. However, data from the National Institute on Drug Abuse (NIDA) show an increase in any LSD use by high school seniors "within the last 12 months" from 4.8% to 5.6% from 1988 to 1992. While the magnitude of this rise is slight, it stands in contrast to the abuse of other drugs. For example, the proportion of seniors who had used any cocaine dropped from 7.9% to 3.1% during the same period. Thus, the proportion of respondents who reported any use of LSD was almost twice as high as the proportion reporting any cocaine use by high school seniors in 1992. The 1990 NIDA statistics reveal that lifetime prevalence rates for hallucinogens were about the same as those for cocaine, and 7 to 8 times higher than for heroin. LSD ranked first in the categories of "most intense" and "longest" high among respondents. Between 13 and 17 million individuals in this country have used a hallucinogen at least once.
Hallucinogens reside in Schedule I of the Controlled Substances Act of 1970, which is reserved for drugs with "high abuse potential," "lack of established safety even under medical supervision," and "no known use in medical treatment". Compounds with "substantially similar" structure or function also are Schedule I drugs, as a result of the passage of the Controlled Substances Analog Bill of 1986. The use of mescaline-containing peyote by the Native American Church has been debated for nearly a century (La. Native American Church members may possess and ingest peyote in several states, and non-Native Americans may use it in Church ceremonies in some. In response to increasing judicial restrictions on peyote use, the Religious Freedom Restoration Act became law in 1993. Interpretation of this law with respect to hallucinogenic "sacraments" by traditional non-Westernand other "neo-religious" groups will be of interest.
The nearly simultaneous discoveries of serotonin (5HT) and LSD undoubtedly have had an impact on the preeminent role of this neurotransmitter in explicating hallucinogens' effects and mechanisms of action. Noradrenergic, dopaminergic, and cholinergicsystems have also been investigated, but have received less attention.andfirst suggested that LSD antagonized the effects of 5-HT in lower animals. Soon thereafter,showed Written by Rick J.that LSD decreased particulate binding of 5-HT in the axon, raising brain levels of 5-HT and lowering those of its metabolite 5-hydroxyindoleacetic acid. 5-HT mechanisms have been demonstrated for electrophysiological, pharmacological, and behavioraleffects of hallucinogens. The animal model of "hallucinogenesis" most used is drug discrimination, wherein animals are trained to distinguish between a hallucinogen, usually LSD, and saline. Animal responses to a test drug as if it were LSD suggest that the "interoceptive" or "discriminative" cue is similar to LSD's. However, several nonhallucinogens are LSD-like in this model, such as quipazineand lisuride, while psilocybin is not, which emphasizes the need for human studies. Hallucinogens were important in stimulating the burgeoning field of 5-HT receptor subtypes. Current data emphasize effects upon the 5-HTlA and 5-HT2A,C subtypes, alone or in combination. Toleranceand cross-toleranceto behavioral effects of hallucinogens is seen rapidly, and is accompanied by downregulation of.
Initial human studies with hallucinogens relied upon careful clinical observation, using psychoanalyticor behavioral) perspectives, in normal subjectsand psychiatric patients. In addition, hallucinogen effects on previously validated psychological scales, such as the MMPI, assessed change scores within individuals and allowed comparisons between hallucinogen-induced syndromes in normal subjects with other well-characterized psychopathological states. Three rating scales were developed specifically for LSD effects in the 1960s. "Normative" data for all three scales were generated from effects in unexperienced hallucinogen users who were not told what the effects of LSD might be, making the data difficult to interpret, particularly when an attempt is made to determine their reinforcing properties in those who use them recreationally. Thescale emphasized somatic, cognitive, and perceptual effects of LSD, while the Linton-Langs scaleassessed effects predicated on a psychoanalytic theory of consciousness. The Addiction Research Center Inventory, the standard rating scale for assessing effects of drugs of abuse, used LSD as one of several mind-altering compounds. Its LSD scale is known as the dysphoria scale, reflecting its emphasis on unpleasant effects. We have developed a new instrument, the Hallucinogen Rating Scale (HRS), that differs from these previous scales. It was drafted by interviewing experienced hallucinogen users, and Written by Rick J.modified during pilot studies with DMT in an additional cohort of well-prepared, educated, well-functioning, experienced hallucinogen users. The HRS also differs from other rating scales in its emphasis on a "mental status examination" clustering of items. In the Abramson et al. scale, derivative factors, such as paranoid ideation and generalized inhibitory effects, are used. The Linton-Langs scale also uses this manner of grouping items: feeling less inhibited and suspiciousness are examples. In the Addiction Research Center Inventory, similarities or differences between a test drug and "reference" drugs are made, without determining the nature of these similarities or differences. In the HRS, items are grouped into six "clinical clusters": somaesthesia (somatic/interoceptive/visceral cues), affect, perception, cognition (thought content and processes), volition (willful ability to interact with one's mental and physical self and the environment), and intensity (a global measure of robustness of response). These clinical clusters provided better resolution of subtle dose effects for DMT than multiple biological measurements in initial dose-response studies. Principal components factor analysis, choosing six factors to correspond to the clinical clusters, also proved superior to biological variables in differentiating among DMT doses, but generated a less heuristically useful grouping of individual items.
Whether LSD and longer-acting compounds produce their effects directly, or require secondary, "downstream" mechanisms, has been debated, because of the delay in onset of effects of LSD even with intravenous administration. However,described nearly instantaneous onset of LSD effects with intraspinal administration, and intravenous DMT effects also are immediate. Thus, access of drug to relevant brain sites, lipid solubility, clearance, and other pharmacokinetic factors determine the time course of drug effects, rather than secondary processes. However, there may be systems downstream from 5-HT receptor agonism that require extremely short time domains for activation.
LSD and other classical compounds elicit behavioral toleranceand cross-toleranceafter several daily doses. The exception is DMT, for which no behavioral tolerance has been demonstrated, and which elicits a fully hallucinogenic response in LSD-tolerant subjects. Written by Rick J.
Serotonin. Bromo-LSD, a potent 5-HT antagonist in lower animals, although psychoactive in humans at much higher doses than LSD, antagonized LSD effects in both normal subjects) and psychiatric patients. Cyproheptadine, a 5-HT2A c antagonist, prevented the subjective effects of DMT in two of three normal volunteers. 5-Hydroxytryptophan loading studies attempted to surmount the 5-HT antagonism of LSD in humans, but did not demonstrate clinically relevant effects. Chronic monoamine oxidase inhibition reduced LSD's effects in humans, perhaps relating to downregulation of 5-HT sites. MAO inhibition also reduced DMT effects. This latter phenomenon may relate to inhibition of DMT metabolism. Reserpine, if administered at adequate dosage and duration, enhanced responses to LSD in humans, supporting a functional "upregulation" of relevant mechanisms. Both meta-chlorophenylpiperazineand 6-chloro-2-(1-piperzinyl)pyrazine (MK-212)share pharmacological characteristics with the classical hallucinogens, and elicit "hallucinogenic" effects in patients with schizophreniaor alcoholism, but not in normal subjects. Higher doses in normal subjects may produce more typical responses. Dopamine. LSD has agonist effects at postsynaptic receptors, and DMT has dopamine-releasing properties. While chlorpromazine was suggested to be a "specific antidote" to LSD effects, it may enhance LSD's effects if given during the acute intoxication. Similarly, haloperidol pretreatment enhanced the neuroendocrine and subjective effects of DMT in one subject. In addition, methamphetamine (a dopamine agonist) ameliorated acute LSD effects. Thus, affinities of hallucinogens for dopamine receptors, relative to primarily dopaminergic or antidopaminergic compounds, may determine the end result of manipulating dopaminergic neurotransmission on responses to hallucinogens. Other. Little data exist regarding manipulating cholinergicand adrenergicsystems on hallucinogen effects in humans, and require further study.
The association between ingestion of hallucinogens and onset of acute schizophrenic episodes is discussed below (see Adverse Effects). One of the initial indications for LSD in clinical research was for elicitation of a time-limited "psychotomimetic" syndrome. However, the degree of overlap has been vigorously debated. The criticism that visual effects were relatively uncommon in functional psychoses has been tempered by the high incidence of these symptoms in later studies). It appears that acutely ill, positive-symptom patients show more "psychedelic" symptoms than do chronic, undifferentiated, negative-symptom predominating patients, particularly in the prodromal state. Hallucinogens also were administered to psychotic patients and comparisons were made between drug effects and preexisting symptoms. These studies were limited by the highly anecdotal nature of ratings of "subjective" effects. Some studies reported that hallucinogens produced different symptoms than those patients were normally experiencing, while others reported an exacerbation of preexisting psychopathology. A relatively consistent finding was that "burned out," predominantly negative symptom-laden patients showed blunted responses to hallucinogens. This latter finding supports lower levels of 5-HT2 sites in the cortex of schizophrenics. It also prompted a search for "endogenous schizotoxins," in which case "tolerance" to naturally occurring psychotomimetics would confer resistance to exogenously administered agents in patients. The short-chained tryptamines, DMT and 5-methoxyDMT, were leading candidates for endogenous hallucinogens. Requisite enzymes for DMT biosynthesis were found in human blood, brain, and lung. Although correlations were seen between acute symptomatology and DMT excretion in patients, interest waned because peripheral DMT levels were not consistently different between normal and psychotic subjects. However, peripheral levels do not accurately reflect either concentrations at discrete brain areas, nor differential sensitivity to comparable levels between normal subjects and patients with psychoses. Lack of tolerance to its psychological effects, given either twice daily for 5 daysor every 30 minutes four times, strengthens its importance as a putative schizotoxin.
Relatively few studies used LSD as a "psychopharmacotherapeutic" agent in humans, i.e., daily dosing regimes. Daily LSD elicited robust antidepressant responses in depressives in an uncontrolled study, while tolerance to its psychedelic effects developed rapidly. These data are consistent with similar effects of chronic LSD and antidepressants on 5-HT receptor function. Beneficial responses to daily dosing in some autistic children also were seen.
Written by Rick J.The first suggestion that LSD may hasten psychotherapy was made in the early 1950s, and series of cases soon followed. LSD was believed useful in recovering early memories, enhancing associative processes, reducing repression, intensifying affective responses, and magnifying aspects of the transference). These early protocols utilized relatively low doses (25 to 100 mcg) within the context of ongoing psychoanalytic psychotherapy. This was termed the psycholytic approach, and utilized multiple sessions over months or years. These studies were hampered by lack of adequate control groups and impartial raters, small sample size, and primarily anecdotal data. However, their emphasis on repeated sessions merits attention when assessing results from "psychedelic" research protocols. This latter approach, described below, may have limited efficacy by depending inordinately upon one or two highly charged sessions, without the benefit of "working through" available in the psycholytic model. The psychedelic approach, favored by North American researchers, involved administration of a single, or at most a small number of, high dose (300 to 1500 mcg) LSD session(s) after a relatively short course of psychotherapy. This psychotherapy encouraged the patient to undergo a "psychedelic experience," which had many aspects of a religious epiphany. As many "spontaneously recovered" drug abusers report similar spiritual-mystical experiences, this approach was turned to substance abuse treatment. Uncontrolled, often anecdotal reports from psychedelic studies also demonstrated some promise in the treatment of sociopathy, prisoner recidivism, and the pain and despair associated with terminal illness. Substance abuse treatment studies were numerous, and while initial reports were enthusiastic, studies using control groups and longer follow-up demonstrated less impressive results. However, a review of 31 studies involving 1100 alcoholics concluded that meaningful generalizations could not be reached because of the inconsistent designs and criteria for improvement. In summary, many of the initial studies suggesting enhancement of psychotherapy with hallucinogens were hampered by lack of methodological rigor. However, placebo/control treatments are problematic. For example, when 50 1lg of LSD were used as "active placebo" against 450,ug of LSD in an alcoholism treatment study using the psychedelic model, minimal differences in outcome among groups were discerned. That many of the low-dose group also underwent a "peak experience" emphasizes the importance of assessing the interplay between pharmacology, psychotherapy, and subjective experience. Minimum requirements for future studies should include independent raters of effects and outcome, identical (nondrug) treatment in the control group, and adequate follow-up (at least 1 year). The choice of inactive and/or active placebo must be given careful consideration. Finally, a hybrid of the psychedelic and psycholytic models, in which more frequent high-dose sessions are used, may provide additional flexibility and allow more psychotherapeutic work to take place than either model alone. Written by Rick J. Strassman Thursday, 07 January 2010 21:16 -Last Updated Monday, 20 December 2010 21:48
The profoundly altered mental status elicited by hallucinogens requires astute clinical management, including thorough screening and preparation of prospective patient or volunteer subjects, careful supervision of drug sessions, and consistent and responsive follow-up which may require psychotherapeutic intervention. Early clinical investigators provided reassuring safety data. A survey of American clinical research documented in normal volunteers a rate of attempted suicide of 0/1,000, completed suicide of 0/1,000, and "psychotic reactions over 48 hours" of.8/1,000. Corresponding figures in patients were 1.2/1,000,.4/1,000, and 1.8/1,000. These data were derived from over 5,000 subjects who had received LSD or mescaline more than 25,000 times, single individuals taking between 1 and 80 doses, using LSD doses from 25 to 1,500 mcg. A British survey reported comparable results. Once hallucinogens escaped from the laboratory, however, emergency rooms and clinics were quickly impacted by adverse effects in unprepared, unsupervised, and psychiatrically ill individuals taking hallucinogens, especially LSD. LSD was nearly always of uncertain quality and dose, and combinations of LSD and other drugs and alcohol were usual. These adverse consequences may be classified temporally as acute, subacute, and chronic.
Acute adverse effects include: a) brief panic reactions to effects of the drug, which generally responded to verbal reassurance and protection of the patient, and only in severe instances, to medication; and b) psychotic reactions, disorganized states that lasted longer than 24 hours and required more intensive management and often hospitalization. These psychotic reactions usually were superimposed on preexisting psychotic disorders in polydrug-abusing patients. They typically responded to treatments appropriate to the non-drug-induced syndromes they resembled. Toxicology laboratories now can measure sub-nanogram/milliliter concentrations of LSD in body fluids, aiding diagnosis of acute adverse reactions.
Written by Rick J.Subacute effects requiring clinical intervention are flashbacks, which refer to unbidden re-experiencing of certain aspects of hallucinogen-induced effects, often visual, but partaking of all psychic functions. They occur after an intervening period of normalcy after a drug experience. Not all flashbacks are felt to be adverse, and many members of the psychedelic subculture find brief "free trips" pleasurable. The incidence is reported to vary between 15% and 77% of individuals who have had at least one LSD experience. In our DMT studies with experienced hallucinogen users, we have seen an incidence of 5% to 10% in volunteers with at least one high-dose DMT session. These sessions, it should be noted, are almost uniformly regarded as "higher than I have ever been," and thus may be considered traumatic. Meditation, smoking marijuana, and falling to or waking from sleep are the most common precipitants. Several volunteers willfully attempt to re-experience aspects of the DMT state by these means. The etiology of flashbacks is not known, but organic, psychological, and social hypotheses have been proposed. Their presence in post-traumatic stress disorder and elicitation by lactate infusionsuggest a complex interaction of anxiety and stress with memory processes. Flashbacks are usually self-limited, if psychoactive drugs, especially hallucinogens and marijuana, are avoided. Persistent or particularly disturbing symptoms) require a neurological evaluation.
Chronic adverse effects may be divided into functional and organic. Functional syndromes rarely may be quite debilitating and treatment resistant, resembling an ego-syntonic, negative symptom-laden schizophrenic disorder. More difficult to diagnosis confidently as directly related to LSD use are changes in lifestyle and interpersonal behaviors associated with hallucinogen use. The confluence of drugs and preexisting personality styles is suggested in10-year follow-up of psychotherapy patients and normal volunteers who participated in sanctioned LSD studies. This study suggested a catalytic effect of LSD use in individuals predisposed to unconventional aesthetic and philosophic ideas. LSD-induced organic central deficits have been difficult to document with certainty, because of no premorbid data and an inability to control for other substances of abuse. Statistically, but not clinically, significant decrements were reported in several studies. Lower Halsteads' Category and Reitan's Trail Making A test scores were reported in hallucinogen users compared with control subjects; however, both of these tests were within normal ranges in drug users. Nonspecific EEG changes also were described. Chronic visual disturbances, posthallucinogen perceptual disorder, akin to chronic flashbacks, may partake of functional and organic bases. The validity of this diagnosis is uncertain because of lack of premorbid data and inability to control for other drugs of abuse. Its responsiveness to
Written by Rick J.benzodiazepines) support an anxiety/functional rather than organic disorder.
Initial reports of chromosomaland reproductivedisorders in LSD users were not replicated in later studies. Until more controlled data are forthcoming, however, woman who are pregnant or not using reliable contraception are not suitable candidates for hallucinogen research protocols.
Hallucinogens are powerful drugs, with the potential to elicit or exacerbate psychiatric symptoms. Particularly aversive or overwhelming acute effects may traumatize or sensitize the individual, setting up the potential for flashbacks akin to those seen in post-traumatic stress disorder. The use of experienced hallucinogen users may reduce the traumatic nature of high-dose hallucinogen sessions, and is recommended for psychopharmacological research. Additionally, truly informed consent is possible only in experienced users. Studies comparing responses in normal subjects with those in psychiatric patients (see below) should use the lowest doses that will generate requisite data. Psychotherapy protocols require a careful assessment of risk to benefit ratios balancing morbidity or mortality of an untreatable psychiatric condition with the likelihood of psychological sequelae of hallucinogen exposure. The risk associated with psychotherapy research protocols may be lessened by using the lowest possible dose of drug. If high-dose administration is necessary, it may be prudent to gradually build up to this dose over several sessions.
In the United States, we have been administering DMT since late 1990in psychopharmacologic studies utilizing experienced hallucinogen users. The University of Miami has begun phase I studies of ibogaine in
Written by Rick J.preparation for substance abuse treatment research. Similar phase I studies have begun at UCLA with MDMA, also in anticipation of therapeutic applications. Psychopharmacological studies using subanesthetic, psychotomimetic doses of ketamine in normal volunteers and patients with schizophrenia are ongoing at Yale University. A substance abuse treatment amendment to the University of Maryland's inactive LSD protocol has been approved, and may begin within a year. In Europe, group and individual psychodynamic psychotherapy with LSD or MDMA has been taking place in Switzerland since 1985, but no research data have been generated. The University of Zurich is studying the effects of psilocybin and ketamine on positron emission tomography and neuropsychological responses in normal volunteers. In Germany, several sites are studying mescaline and MDE (the N-ethyl derivative of MDMA) effects in normal volunteers, studies in which multiple neurobiological variables are characterized.
As described previously, a wide range of temporal characteristics are available with the hallucinogens, and may be exploited for research with different goals. For example, psychotherapy protocols might be best served using short-acting drugs whose effects last between 1 and 2 hours, while neuroendocrine challenge studies would benefit from using ultra-short-acting drugs and keeping interactions with the environment to a minimum. Protocols requiring multiple within-individual assessments could use long-and ultra-long-acting drugs.
Recent DMT studies demonstrate the superiority of subjective (HRS) responses to biological ones with respect to subtle dose effects. Thus, despite better characterization of mechanisms of action for neuroendocrine, cardiovascular, and other autonomic variables, sensitivity for effects of experimental manipulations is relatively low. This emphasizes the importance of introspection and subjective data in characterizing the effects of hallucinogens, especially using a within-subjects design. Written by Rick J.
Human hallucinogen psychopharmacology requires further study, for both clinical and heuristic purposes. Research should assess the role of non-5-HT neurotransmitters, particularly dopamine. Risperidone, with potent 5-HT2 and D2 antagonism, is more potent than ritanserin, a pure 5-HT2A,( agent, in antagonizing animal responses to LSD. The importance of combined 5-HT/DA antagonism corresponds to efficacy in schizophrenia treatment with "atypical" antipsychotic medications, and suggests that antagonists to hallucinogens' behavioral effects in humans may be efficacious in schizophrenia. Pretreatment blockade studies, based upon relevant animal and human data, will suggest interruption strategies for acute adverse reactions in the emergency setting. Blockade strategiesalso could be utilized to prevent subjective effects in those prone to chronic abuse of hallucinogens in a manner similar to naltrexone. Although most classical hallucinogens' qualitative psychopharmacological properties are believed identical, little data exist for within-subject studies using multiple drugs. Many congeners of classical compounds have been administered safely to humans. Assessment of salient similarities and differences will suggest structure-activity relationships for design of drugs with desirable functional profiles for clinical research purposes. Responses to hallucinogens in psychiatric populations with presumed abnormalities in neurotransmitter systems relevant to hallucinogen action may be tested, if appropriate safeguards are in place. Such studies would generate unique human data relating disturbed subjective experience in psychiatric patients to pharmacological manipulations, generating both therapeutically and mechanistically valuable data. Studies exploiting recently developed hallucinogen-induced animal models of information-processing defects in schizophrenia) could be applied to normal volunteers' responses to these drugs, further comparing the two syndromes. In addition, the HRS could be applied to more carefully characterized schizophrenic patients at various stages of the disorder, allowing novel comparisons between functional and drug-induced psychoses. Advances in in vivo brain-imaging techniques may better characterize hallucinogen effects and mechanisms of action. These include topographic pharmacoelectroencephalography, positron emission tomography (assessing metabolic effects of psychoactive doses, and distribution of low doses of labeled compounds), and magnetic resonance imaging (spectroscopy and functional imaging).
Economic constraints create increasing pressure for cost-effective medical psychotherapy. Sophisticated psychotherapy protocols with proven efficacy
Written by Rick J.) provide a strong foundation upon which hallucinogen-assisted psychotherapy research may be re-examined. Courses of therapy utilizing adjunctive, high-dose, hallucinogen-assisted sessions should be considered in a model combining the psychedelic and psycholytic models. This would be a logical extension of earlier work that suggested robust short-term improvement, but less impressive maintenance of therapeutic effects, in high-dose models. The growing numbers of terminally ill cancer and acquired immune deficiency syndrome patients who require palliative, quality-of-life treatment suggest additional areas for future psychotherapy research that would build upon older, uncontrolled studies indicating beneficial responses. The reported elements of increased pain control, improved family relationships, and greater acceptance of illness and impending death, if verified by controlled studies, would provide additional clinical support for these patients. The use of "flooding" to treat post-traumatic stress disorder in both combat veteransand others) may also provide a unique interfacing of hallucinogenic drug effects with an established treatment modality for a particularly pernicious and common disorder. Hallucinogen-enhanced imagery and associations, and associated affective responses to these, could be used to enhance the efficacy of this treatment.
Although complex and potentially controversial, set and setting issues require further study. Set refers to the personality, state, and expectations of the subject, and setting to the environment in which the session takes place. Setting partakes of the physical surroundings, e.g., inpatient, high-technology research unit or comfortable outpatient consultation suite; nuances of the investigator/therapist presentation, including clothing, appearance, odor, and other physical characteristics; being belted to the bedor able to move about freely; and eyes open or blindfolded. In addition, it involves the "set" of the research team members, including the nature of countertransference and empathy, type and amount of training in psychotherapy and working with regressed/psychotic individuals, and the theoretical model and expectations of the research, psychotomimetic, psychedelic, or otherwise. Finally, research team members' experience with hallucinogens may affect the nature of the results of research/treatment protocols. Swiss and German health authorities require that the principal investigators first take study drugs at doses to be used in their protocols, both for safety issues and to provide more adequate informed consent.3 In the United States, self-experimentation by research teams initially was encouraged. However, in response to highly publicized cases of self-experimentation and extraresearch drug taking with volunteers, this practice was discontinued. Future research must carefully account for these setting variables in assessing outcome measures, and the European practice of "going first" should be considered. Written by Rick J.
The small number of protocols using hallucinogens allows for very close contact between investigators and regulatory agencies overseeing this work. However, renewed examination of these compounds may generate a large number of requests to use them in clinical studies. State of the art methodologies are no guarantee against disasters resulting from imprudent administration of hallucinogens to humans. Transference and countertransference issues are rarely discussed in psychopharmacology research, and increasingly less so in psychotherapy research. However, the regressed, suggestible, and unusual behavior of subjects under the influence of hallucinogens is easily observable. Interpersonal exchanges that would be readily overlooked in a normal state of awareness may assume extreme and confusing meaning. The clinical investigator not only may become the object of infantile wishes and fears, but may, in the subject's mind, actually look, smell, feel, and sound identical to highly emotionally charged people in his or her life. In addition, the clinical researcher may have multiple, conflicting, and more-or-less conscious motivations for administering incapacitating drugs to humans. These may include narcissistic, grandiose or sadistic, and voyeuristic impulses. Callous, offhand, or teasing remarks made for these and other, less malignant, but similarly unexamined, motivations can dramatically alter the course of a volunteer's hallucinogenic drug experience, from a psychedelic to psychotomimetic. Sexual relations between clinician and subject, during or after a hallucinogenic drug session, the most disastrous acting-out of both parties' drug-altered sensibilities, do occur. Regulatory agencies determine professional qualifications and adequacy of facilities for conducting this research. However, I believe that specialized training, and perhaps certification, is necessary for clinical investigators performing human hallucinogen research. Such training/certification and ongoing periodic supervision would reduce the likelihood of subtle or flagrant misuse of these compounds by unknowing or unscrupulous clinical investigators. Specific proposals regarding the nature of this training and supervision is beyond the scope of this article. This suggestion is meant to stimulate further debate and discussion at institutional and governmental levels.
The renewal of human hallucinogen research is encouraging. However, it must be tempered with an appreciation that the controversial nature of these drugs caused a suspension of nearly a generation's worth of research in the field. Ongoing studies are taking a painstaking, systematic approach, and are avoiding claims that cannot be substantiated by data. Careful attention to selection, screening, preparation, supervision, and follow-up of subjects undergoing hallucinogenic drug sessions is absolutely necessary. In addition, the training, characteristics, and research setting of clinical investigators desiring to work with these compounds must be addressed directly.
Create a free account to open full-text PDFs.
Papers in Blossom that reference this study
Walker, J., Deering, D., Unger, B. H. · Journal of Psychoactive Drugs (2026)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)
O'shaughnessy, D. M., Berlowitz, I., Rodd, R. et al. · Therapeutic Advances in Psychopharmacology (2021)
Alamia, A., Timmermann, C., Carhart-Harris, R. L. · eLife (2020)
Chi, T., Gold, J. A. · Journal of the Neurological Sciences (2020)
Ezquerra-Romano, I. I., Lawn, W., Krupitsky, E. M. et al. · Neuropharmacology (2018)
Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)
Dorsen, C., Palamar, J., Shedlin, M. G. · Addiction Research and Theory (2018)
Belouin, S. J., Henningfield, J. E. · Neuropharmacology (2018)
Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)
Phelps, J. · Journal of Humanistic Psychology (2017)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Danforth, A. L., Struble, C., Yazar-Klosinski, B. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Frecska, E., Szabo, A., Winkelman, M. J. et al. · Translational Neurosciences (2013)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Mangini, M. · Journal of Psychoactive Drugs (2011)
Jacob, M. S., Presti, D. E. · Medical Hypotheses (2005)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Krupitsky, E. M., Burakov, A. M., Romanova, T. N. et al. · Journal of Substance Abuse Treatment (2002)
Delgado, P. L., Moreno, F. A. · Journal of Psychoactive Drugs (1998)